NCT02636036View on ClinicalTrials.gov

Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

January 25, 2016

Primary Completion Date

October 8, 2021

Study Completion Date

October 8, 2021

Conditions
Colorectal CancerSquamous Cell Carcinoma of the Head and NeckEpithelial Tumor
Interventions
BIOLOGICAL

enadenotucirev

BIOLOGICAL

nivolumab

Trial Locations (6)

47905

Horizon Oncology Research, 1345 Unity Place, Suite 365, Lafayette

48202

Henry Ford Hospital, 2799 West Grand Blvd., Detroit

85724

University of Arizona Cancer Center, 1515 North Campbell Ave., Tucson

90095

UCLA Medical Center, 10945 Le Conte Ave, Ste. 3360, Santa Monica

91010

City of Hope Comprehensive Cancer Center, 1500 E Duarte Str., Duarte

37232-6307

Vanderbilt-Ingram Cancer Center, Nashville

Sponsors

Lead Sponsor

Akamis Bio
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Syneos Health

OTHER

lead

Akamis Bio

INDUSTRY